Incyte Corporation Release: Data Presented at 2013 American Society of Clinical Oncology Offers First Evidence that Long-Term Treatment with Jakafi® (ruxolitinib) May Stabilize or Reverse Bone Marrow Fibrosis, a Key Marker of Worsening Disease in Patients

Published: Jun 04, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Incyte Corporation (Nasdaq: INCY) announced that results from an exploratory analysis of bone marrow fibrosis data from an ongoing Phase I/II single-arm, open-label clinical trial for Jakafi® (ruxolitinib) were presented today at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Fibrosis of the bone marrow, a cardinal feature of myelofibrosis (MF), was shown to stabilize or reverse after 24 and 48 months of Jakafi treatment in the majority of patients with MF, a magnitude of an effect not seen with long-term treatment with hydroxyurea. Jakafi, an oral JAK1 and JAK2 inhibitor, is FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis.

Help employers find you! Check out all the jobs and post your resume.

Back to news